Patents expiring in 2037

US 9539234

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. · Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9549913

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. · Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9549940

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. · Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 2017020867

USE OF MASITINIB FOR THE TREATMENT OF CROHN'S DISEASE

AB SCIENCE [FR] · Granted Thu Jan 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9555004

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. · Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9562223

Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP)

HALOZYME, INC. · Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9561229

Emulsion formulations of aprepitant

Heron Therapeutics, Inc. · Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9579324

Therapeutically active compounds and their methods of use

Agios Pharmaceuticals, Inc. · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9580427

Kinase inhibitors

The Regents of the University of California · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9585878

Treatment of BDNF-related disorders using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9586955

Compounds for treating spinal muscular atrophy

PTC THERAPEUTICS, INC. · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9593333

Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations

Ionis Pharmaceuticals, Inc. · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9592207

Intranasal administration of ketamine to treat depression

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9592227

Compositions of a polyorthoester and an aprotic solvent

Heron Therapeutics, Inc. · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9593066

Process to prepare treprostinil, the active ingredient in remodulin®

United Therapeutics Corporation · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9603796

Controlled release antimicrobial compositions and methods for the treatment of otic disorders

The Regents of the University of California · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9603806

Pharmaceutical compositions for the treatment of Helicobacter pylori

RedHill Biopharma Ltd. · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9604901

Process to prepare treprostinil, the active ingredient in Remodulin®

United Therapeutics Corporation · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9603853

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9617596

Biomarkers predictive for clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9617303

Sustained-release composition and method for producing the same

Takeda Pharmaceutical Company Limited · Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

CA 3000894

TRAITEMENT DE LA MASTOCYTOSE SYSTEMIQUE GRAVE PAR LE MASITINIB

AB SCIENCE [FR] · Granted Thu Apr 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9625473

Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9622983

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9631193

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9631001

Peptide antagonists of the vasopressin-2 receptor

Universität Regensburg · Granted Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9636408

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

WO 2017072335

UTILISATION DE MASITINIB ET D'AUTRES INHIBITEURS DE MASTOCYTE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

AB SCIENCE [FR] · Granted Thu May 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 2017119760

USE OF MASITINIB FOR THE TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

AB SCIENCE [FR] · Granted Thu May 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9649284

Treating critically ill patients with intravenous ibuprofen

Cumberland Pharmaceuticals Inc. · Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9649364

Methods for producing stable therapeutic formulations in aprotic polar solvents

XERIS PHARMACEUTICALS, INC. · Granted Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9655969

Inhalable medicament comprising tiotropium

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9662396

Stable aqueous formulations of etanercept

Coherus BioSciences, Inc. · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9662338

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9662322

Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9669069

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9670492

Modulation of prekallikrein (PKK) expression

Ionis Pharmaceuticals, Inc. · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9670163

Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Vertex Pharmaceuticals Incorporated · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9677062

Hyaluronidase and factor VIII compositions

HALOZYME, INC. · Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9675639

Peroxide formulations and methods and applicators for using the same

Aclaris Therapeutics, Inc. · Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9677061

Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

HALOZYME, INC. · Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9682075

Tamper-resistant pharmaceutical compositions of opioids and other drugs

Collegium Pharmaceutical, Inc. · Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9682080

Pyruvate kinase activators for use in therapy

Agios Pharmaceuticals, Inc. · Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9687454

Sublingual and buccal film compositions

Indivior UK Limited · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9687522

Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9694079

Long-acting polymeric delivery systems

Heron Therapeutics, Inc. · Granted Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9701636

Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Akebia Therapeutics, Inc. · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9701611

Salts of treprostinil

United Therapeutics Corporation · Granted Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)